These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 35329878)
1. Clinical Outcomes of an Innovative Cefazolin Delivery Program for MSSA Infections in OPAT. Herrera-Hidalgo L; Luque-Márquez R; de Alarcon A; Guisado-Gil AB; Gutierrez-Gutierrez B; Navarro-Amuedo MD; Praena-Segovia J; Carmona-Caballero JM; Fraile-Ramos E; Gutierrez-Valencia A; Lopez-Cortes LE; Gil-Navarro MV J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329878 [TBL] [Abstract][Full Text] [Related]
2. Twice daily cefazolin is effective for treatment of serious methicillin-sensitive Birrell MT; Fuller A Ther Adv Infect Dis; 2019; 6():2049936119882847. PubMed ID: 31839941 [TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Ceftriaxone in the Treatment of Methicillin-Susceptible Ganguly A; de la Flor C; Alvarez K; Brown LS; Mang NS; Smartt J; King H; Perl TM; Filizola H; Bhavan KP Ann Pharmacother; 2023 Apr; 57(4):425-431. PubMed ID: 35942602 [TBL] [Abstract][Full Text] [Related]
4. Outcomes of Outpatient Parenteral Antimicrobial Therapy With Ceftriaxone for Methicillin-Susceptible Hamad Y; Connor L; Bailey TC; George IA Open Forum Infect Dis; 2020 Sep; 7(9):ofaa341. PubMed ID: 32908944 [TBL] [Abstract][Full Text] [Related]
5. Outcomes of Ceftriaxone Compared With Cefazolin or Nafcillin/Oxacillin for Outpatient Therapy for Methicillin-Sensitive Hamad Y; Nickel KB; Olsen MA; George IA Open Forum Infect Dis; 2024 Feb; 11(2):ofad662. PubMed ID: 38352150 [TBL] [Abstract][Full Text] [Related]
6. Outpatient parenteral antimicrobial therapy for the treatment of methicillin-susceptible Staphylococcus aureus: a comparison of cefazolin and ceftriaxone. Winans SA; Luce AM; Hasbun R Infection; 2013 Aug; 41(4):769-74. PubMed ID: 23686435 [TBL] [Abstract][Full Text] [Related]
7. Comparative evaluation of the tolerability of cefazolin and nafcillin for treatment of methicillin-susceptible Staphylococcus aureus infections in the outpatient setting. Youngster I; Shenoy ES; Hooper DC; Nelson SB Clin Infect Dis; 2014 Aug; 59(3):369-75. PubMed ID: 24785233 [TBL] [Abstract][Full Text] [Related]
8. Role of outpatient parenteral antibiotic therapy in the treatment of community acquired skin and soft tissue infections in Singapore. Chan M; Ooi CK; Wong J; Zhong L; Lye D BMC Infect Dis; 2017 Jul; 17(1):474. PubMed ID: 28683717 [TBL] [Abstract][Full Text] [Related]
9. A Comparison of Cefazolin Versus Ceftriaxone for the Treatment of Methicillin-Susceptible Carr DR; Stiefel U; Bonomo RA; Burant CJ; Sims SV Open Forum Infect Dis; 2018 May; 5(5):ofy089. PubMed ID: 30568987 [TBL] [Abstract][Full Text] [Related]
10. Comparative Effectiveness of Cefazolin Versus Nafcillin or Oxacillin for Treatment of Methicillin-Susceptible Staphylococcus aureus Infections Complicated by Bacteremia: A Nationwide Cohort Study. McDanel JS; Roghmann MC; Perencevich EN; Ohl ME; Goto M; Livorsi DJ; Jones M; Albertson JP; Nair R; O'Shea AMJ; Schweizer ML Clin Infect Dis; 2017 Jul; 65(1):100-106. PubMed ID: 28379314 [TBL] [Abstract][Full Text] [Related]
11. Implementation of a cefazolin-based stewardship pathway for methicillin-susceptible Staphylococcus aureus bloodstream infections paired with infectious diseases consultation. Lee BJ; Rao SN; Wang SK; Lee JY; Lakada IY; Gilbert EM; Barr VO; Postelnick MJ; Sutton SH; Zembower TR; Bolon M; Scheetz MH; Rhodes NJ Int J Antimicrob Agents; 2017 May; 49(5):650-654. PubMed ID: 28279787 [TBL] [Abstract][Full Text] [Related]
12. Clinical implications of cefazolin inoculum effect and β-lactamase type on methicillin-susceptible Staphylococcus aureus bacteremia. Lee S; Kwon KT; Kim HI; Chang HH; Lee JM; Choe PG; Park WB; Kim NJ; Oh MD; Song DY; Kim SW Microb Drug Resist; 2014 Dec; 20(6):568-74. PubMed ID: 25000230 [TBL] [Abstract][Full Text] [Related]
13. Cefazolin versus cloxacillin as definitive antibiotic therapy for methicillin-susceptible Staphylococcus aureus spinal epidural abscess: a retrospective cohort study. Bai AD; Findlater A; Irfan N; Singhal N; Loeb M Int J Antimicrob Agents; 2021 Nov; 58(5):106429. PubMed ID: 34469802 [TBL] [Abstract][Full Text] [Related]
14. A comparison of safety and outcomes with cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bloodstream infections. Miller MA; Fish DN; Barber GR; Barron MA; Goolsby TA; Moine P; Mueller SW J Microbiol Immunol Infect; 2020 Apr; 53(2):321-327. PubMed ID: 30190234 [TBL] [Abstract][Full Text] [Related]
16. Treatment outcomes with cefazolin versus oxacillin for deep-seated methicillin-susceptible Staphylococcus aureus bloodstream infections. Rao SN; Rhodes NJ; Lee BJ; Scheetz MH; Hanson AP; Segreti J; Crank CW; Wang SK Antimicrob Agents Chemother; 2015 Sep; 59(9):5232-8. PubMed ID: 26077253 [TBL] [Abstract][Full Text] [Related]
17. Comparison of Nafcillin and Cefazolin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia. Twilla JD; Algrim A; Adams EH; Samarin M; Cummings C; Finch CK Am J Med Sci; 2020 Jul; 360(1):35-41. PubMed ID: 32376001 [TBL] [Abstract][Full Text] [Related]
18. Comparative outcomes of cefazolin versus antistaphylococcal penicillins in methicillin-susceptible Staphylococcus aureus infective endocarditis: a post hoc analysis of a prospective multicentre French cohort study. Lecomte R; Bourreau A; Deschanvres C; Issa N; Le Turnier P; Gaborit B; Chauveau M; Leroy AG; Le Tourneau T; Caillon J; Camou F; Boutoille D Clin Microbiol Infect; 2021 Jul; 27(7):1015-1021. PubMed ID: 32950711 [TBL] [Abstract][Full Text] [Related]
19. Clinical Effectiveness of Continuous Infusion Flucloxacillin in the Outpatient Parenteral Antimicrobial Therapy (OPAT) Setting in a UK Hospital: A Service Evaluation. Clarkson AM; Snape S Antibiotics (Basel); 2024 Feb; 13(2):. PubMed ID: 38391538 [TBL] [Abstract][Full Text] [Related]
20. Impact of Cefazolin Shortage on Clinical Outcomes of Adult Patients with Bacteremia Caused by Methicillin-Susceptible Uda A; Onuma K; Shigemura K; Kitagawa K; Yan Y; Osawa K; Yano I; Miyara T Antibiotics (Basel); 2021 Oct; 10(10):. PubMed ID: 34680827 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]